Our model
The Cumulus business model takes a fresh approach to drug development. A robust asset curation engine is fused with the allocation of seed capital and experienced drug discovery team members, underpinning our biotech company build model.
Our selection
process
Cumulus Oncology is actively engaged in the search for new targets / assets / opportunities / technology platforms that have great potential to have a future as an oncology therapeutic or drive multiple therapeutic options.
Cumulus actively scouts and reviews data packages that present unique market opportunities in Oncology. Partnerships with a range of platform technology companies further enhance our access to new targets. The primary focus is on rigorous scientific review and assessment of the commercial potential of each opportunity. Following this, Cumulus de-risks opportunities through a series of bespoke validation experiments, leveraging in-house data science and bioinformatics to enhance decision-making.
Meet our spin-outs
Cumulus has curated and created a number of oncology biotech spin-out companies, with further other opportunities in development.
